Research Project

Project Title:	Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis (DUET)
Project Type:	Clinical Trial, Enrolment terminated
Disease group(s):	Hereditary glomerulopathies
Project Summary:	The purpose of this trial is to quantify the anti-proteinuric efficacy and to profile the safety of Sparsentan administration in patients with FSGS.
Lead principal investigator(s):	Loreto Gesualdo, Bari
Co-investigator(s):	L Ricciato, Bari V Pavone, Bari
Project Period:	10/2015 - 05/2025
ClinicalTrials.gov:	NCT01613118